Literature DB >> 22574989

Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities.

Zeyu Xiao1, Omid C Farokhzad.   

Abstract

With advances in aptamer selection technologies and nanomedicine, aptamer-functionalized nanoparticles are being explored as promising platforms for targeted therapeutic and diagnostic applications. In this Perspective, we outline recent progress in this field, as exemplified by Bamrungsap et al. in this issue of ACS Nano. Furthermore, we highlight the challenges and opportunities in translating current proof-of-concept designs into in vivo applications, with emphasis on the intrinsic properties of aptamers and their interplay with nanoparticles. With continuous efforts, we expect aptamer-functionalized nanoparticles to advance from preclinical into clinical development for further evaluation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22574989      PMCID: PMC3420009          DOI: 10.1021/nn301869z

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  47 in total

1.  Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells.

Authors:  Joshua K Herr; Joshua E Smith; Colin D Medley; Dihua Shangguan; Weihong Tan
Journal:  Anal Chem       Date:  2006-05-01       Impact factor: 6.986

2.  Aptamers evolved from live cells as effective molecular probes for cancer study.

Authors:  Dihua Shangguan; Ying Li; Zhiwen Tang; Zehui Charles Cao; Hui William Chen; Prabodhika Mallikaratchy; Kwame Sefah; Chaoyong James Yang; Weihong Tan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-27       Impact factor: 11.205

3.  Nucleic acid aptamers for target validation and therapeutic applications.

Authors:  P Shannon Pendergrast; H Nicholas Marsh; Dilara Grate; Judith M Healy; Martin Stanton
Journal:  J Biomol Tech       Date:  2005-09

Review 4.  Nanoparticle-aptamer bioconjugates for cancer targeting.

Authors:  Omid C Farokhzad; Jeffrey M Karp; Robert Langer
Journal:  Expert Opin Drug Deliv       Date:  2006-05       Impact factor: 6.648

Review 5.  Cancer nanotechnology: opportunities and challenges.

Authors:  Mauro Ferrari
Journal:  Nat Rev Cancer       Date:  2005-03       Impact factor: 60.716

6.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.

Authors:  Omid C Farokhzad; Jianjun Cheng; Benjamin A Teply; Ines Sherifi; Sangyong Jon; Philip W Kantoff; Jerome P Richie; Robert Langer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-10       Impact factor: 11.205

7.  Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.

Authors:  Omid C Farokhzad; Sangyong Jon; Ali Khademhosseini; Thanh-Nga T Tran; David A Lavan; Robert Langer
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

8.  Cancer cell targeting using multiple aptamers conjugated on nanorods.

Authors:  Yu-Fen Huang; Huan-Tsung Chang; Weihong Tan
Journal:  Anal Chem       Date:  2008-01-01       Impact factor: 6.986

9.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.

Authors:  Frank Gu; Liangfang Zhang; Benjamin A Teply; Nina Mann; Andrew Wang; Aleksandar F Radovic-Moreno; Robert Langer; Omid C Farokhzad
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-13       Impact factor: 11.205

10.  Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells.

Authors:  Colin D Medley; Joshua E Smith; Zhiwen Tang; Yanrong Wu; Suwussa Bamrungsap; Weihong Tan
Journal:  Anal Chem       Date:  2008-01-17       Impact factor: 6.986

View more
  28 in total

1.  Materiomics for Oral Disease Diagnostics and Personal Health Monitoring: Designer Biomaterials for the Next Generation Biomarkers.

Authors:  Wenjun Zhang; Ming L Wang; Sammy Khalili; Steven W Cranford
Journal:  OMICS       Date:  2016-01

Review 2.  Nanomedicine therapeutic approaches to overcome cancer drug resistance.

Authors:  Janet L Markman; Arthur Rekechenetskiy; Eggehard Holler; Julia Y Ljubimova
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

Review 3.  Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.

Authors:  Gregory Benedetto; C Greer Vestal; Christine Richardson
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

Review 4.  Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy.

Authors:  Zijian Zhou; Jibin Song; Liming Nie; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2016-11-21       Impact factor: 54.564

Review 5.  Aptamers and their applications in nanomedicine.

Authors:  Hongguang Sun; Youli Zu
Journal:  Small       Date:  2015-02-11       Impact factor: 13.281

6.  Aptamer-Based High-Throughput Screening Model for Efficient Selection and Evaluation of Natural Ingredients against SGIV Infection.

Authors:  Hongling Wei; Zhongbao Guo; Yu Long; Mingzhu Liu; Jun Xiao; Lin Huang; Qing Yu; Pengfei Li
Journal:  Viruses       Date:  2022-06-08       Impact factor: 5.818

7.  Nanolayered siRNA dressing for sustained localized knockdown.

Authors:  Steven Castleberry; Mary Wang; Paula T Hammond
Journal:  ACS Nano       Date:  2013-05-17       Impact factor: 15.881

8.  Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells.

Authors:  Fujian Huang; Mingxu You; Tao Chen; Guizhi Zhu; Haojun Liang; Weihong Tan
Journal:  Chem Commun (Camb)       Date:  2014-03-21       Impact factor: 6.222

9.  An Aptamer-Nanotrain Assembled from Six-Letter DNA Delivers Doxorubicin Selectively to Liver Cancer Cells.

Authors:  Liqin Zhang; Sai Wang; Zunyi Yang; Shuichi Hoshika; Sitao Xie; Jin Li; Xigao Chen; Shuo Wan; Long Li; Steven A Benner; Weihong Tan
Journal:  Angew Chem Int Ed Engl       Date:  2019-11-19       Impact factor: 15.336

Review 10.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

Authors:  Nicolas Bertrand; Jun Wu; Xiaoyang Xu; Nazila Kamaly; Omid C Farokhzad
Journal:  Adv Drug Deliv Rev       Date:  2013-11-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.